High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy

Background: The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection....

Full description

Bibliographic Details
Main Authors:	I-Ping Yang, Zhi-Feng Miao, Ching-Wen Huang, Hsiang-Lin Tsai, Yung-Sung Yeh, Wei-Chih Su, Tsung-Kun Chang, Se-fen Chang, Jaw-Yuan Wang
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-08-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835919866964

Similar Items

Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
by: Bertrand Le Roy, et al.
Published: (2016-01-01)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
by: Huang Che-Jen, et al.
Published: (2008-11-01)

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
by: Diana Groza, et al.
Published: (2018-05-01)

Analysis of capecitabine plus oxaliplatin (xelox) combination in the management of metastatic colorectal cancer compare with fluorouracil and oxaliplatin combination (folfox)
by: Isnatin Miladiyah
Published: (2016-12-01)

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy
by: Tao Y, et al.
Published: (2019-04-01)

Efficacy and toxicity of capecitabine/oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) in adjuvant and metastatic treatment of colorectal cancer in patients at the Southern Arizona Veteran Affairs Health Care System
by: Cushing, Merta, et al.
Published: (2017)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
by: Yun-Ting Lou, et al.
Published: (2014-01-01)

Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy
by: Peng-Chan Lin, et al.
Published: (2021-03-01)

Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy
by: Gui-Nan Lin, et al.
Published: (2016-01-01)

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
by: Kazuaki Harada, et al.
Published: (2019-03-01)

Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
by: Mehdi Dehghani, et al.
Published: (2015-07-01)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
by: Bai L, et al.
Published: (2019-12-01)

Cognitive and physical function in individuals treated with adjuvant FOLFOX chemotherapy for colon cancer : pilot study
by: Niksirat, Negin
Published: (2014)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
by: Vincenza Conteduca, et al.
Published: (2018-12-01)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
by: Dae-Won Lee, et al.
Published: (2019-05-01)

A novel approach to enhancing the effectiveness of chemotherapy : combining curcumin with FOLFOX chemotherapy for metastatic colorectal cancer
by: Irving, Glen Robert Bell
Published: (2014)

Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
by: Ji Hoon Choi, et al.
Published: (2014-01-01)

Colorectal cancer surgery patients received adjuvant chemotherapy investigate the effectiveness
by: Yi-Ju Huang, et al.
Published: (2015)

Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients
by: Kong Ying, et al.

All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial
by: Jie Shi, et al.
Published: (2019-04-01)

Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
by: Eric Chung, et al.
Published: (2019-12-01)

Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma
by: Jiayi Han, et al.
Published: (2020-09-01)

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study
by: Marie Selvy, et al.
Published: (2020-07-01)

Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event
by: Henriette Quack, et al.
Published: (2013-12-01)

Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
by: Chikako Funasaka, et al.
Published: (2019-08-01)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
by: Jii Bum Lee, et al.
Published: (2020-04-01)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
by: Touroutoglou Nikolaos, et al.
Published: (2007-05-01)

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
by: Marica Garziera, et al.
Published: (2017-06-01)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
by: Huabin Hu, et al.
Published: (2020-12-01)

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model
by: Yiyi Zhang, et al.
Published: (2021-01-01)

FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
by: Yue Guan, et al.
Published: (2020-04-01)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
by: Portales Fabienne, et al.
Published: (2009-09-01)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
by: Bożena Cybulska-Stopa, et al.
Published: (2020-03-01)

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
by: Luiz Carlos Porcello Marrone, et al.
Published: (2013-01-01)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
by: Taku Naiki, et al.
Published: (2017-11-01)

Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer.
by: Sharon Pattison, et al.
Published: (2017-01-01)

Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer
by: Lui Ng, et al.
Published: (2015-01-01)

UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer
by: Congcong Zhu, et al.
Published: (2021-05-01)

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
by: Guoxiu Wang, et al.
Published: (2018-05-01)

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
by: Maria Sfakianaki, et al.
Published: (2020-07-01)

Cannot write session to /tmp/vufind_sessions/sess_o514ladq7n2jphhf8rju88o2v0